In the ARROW trial, patients with advanced RET fusion NSCLC were treated with BLU-667 achieving a high response rate (ORR 60% (95% CI 42–76) in chemo-pretreated patients) and great intracranial activity [118]. The gene discussed is RET; the disease is non-small cell lung carcinoma.